BAP1 and neoplasm: For VHL wild-type tumors, other therapy modalities aiming at pVHL non-related pathways controlled by tumor suppressors such as PBRM1, SETD2 or BAP1 may be more appropriate than the common anti-angiogenic treatment [56–64].